未登录

M

Mariam Hassan

University of Illinois Chicago

H指数:11

被引数:1,249

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Critical Function of SIK3 in Androgen-Producing Ovarian Theca Cells for Female Reproductive Competence

SIK3在雄激素产生卵巢泡膜细胞中对女性生殖能力的关键作用

IF3.3

2026-09-180

PRE

Monoacylglycerol Lipase and Cyclooxygenase-2 Expression in Osteoarthritic Human Knees

单酰甘油脂肪酶和Cyclooxygenase-2在骨关节炎人类膝关节中的表达

CANNABIS AND CANNABINOID RESEARCH

IF2.7

2024-10-010

PRE

SIK2 and SIK3 Differentially Regulate Mouse Granulosa Cell Response to Exogenous Gonadotropins In Vivo

IF3.3

2024-08-190

OA

Salt-inducible kinases regulate androgen synthesis in theca cells by enhancing CREB signaling

MOLECULAR AND CELLULAR ENDOCRINOLOGY

IF3.6

2023-11-013

OAAI

The HACE1 E3 ligase mediates RAC1-dependent control of mTOR signaling complexes

HACE1 E3连接酶介导mTOR信号复合物的RAC1-dependent控制

IF6.2

2023-10-172

OA

DOES INFLAMMATION PREDICT SUCCESSFUL PLEURODESIS? A POST HOC ANALYSIS FROM THE TIME 1 TRIAL

IF7.7

2017-11-150

OAAI

COST-EFFECTIVENESS ANALYSIS OF LURASIDONE VERSUS QUETIAPINE XR IN PATIENTS WITH BIPOLAR DEPRESSION

VALUE IN HEALTH

IF6

2014-05-010

OAAI

MEDIATION ANALYSIS OF EFFECT OF LURASIDONE ON PATIENT FUNCTIONING IN BIPOLAR DEPRESSION: DIRECT EFFECTS AND INDIRECT EFFECTS MEDIATED THROUGH IMPROVEMENT IN DEPRESSION SYMPTOMS

VALUE IN HEALTH

IF6

2014-05-010

OAAI

THE EFFECT OF LURASIDONE ON FUNCTIONAL REMISSION AMONG PATIENTS WITH BIPOLAR DEPRESSION

VALUE IN HEALTH

IF6

2014-05-010

OAAI

RISK REDUCTION AND NUMBERS NEEDED TO TREAT TO AVOID METABOLIC SYNDROME: 12-MONTH CARDIOMETABOLIC PARAMETERS CHANGES AMONG SCHIZOPHRENIA SUBJECTS TREATED WITH LURASIDONE OR QUETIAPINE XR

SCHIZOPHRENIA RESEARCH

IF3.5

2014-04-010

PREAI

Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia

lurasidone治疗患者的健康相关生活质量: 精神分裂症患者的switch试验结果

IF3.6

2014-02-239

OAAI

IMPACT OF METABOLIC COMORBIDITIES ON INPATIENT COST AND REHOSPITALIZATION RATES FOR PATIENTS DIAGNOSED WITH SCHIZOPHRENIA

VALUE IN HEALTH

IF6

2013-05-010

OAAI

DIRECT AND INDIRECT COSTS AMONG US EMPLOYEES WITH AND WITHOUT BIPOLAR DISORDER OR SCHIZOPHRENIA: ANNUAL COST TRENDS FROM 2001 TO 2011

VALUE IN HEALTH

IF6

2013-05-010

OAAI

EVALUATION OF HEALTH RELATED QUALITY OF LIFE OUTCOMES AMONG PATIENTS WITH SCHIZOPHRENIA SWITCHED TO LURASIDONE FROM OTHER ANTIPSYCHOTICS

VALUE IN HEALTH

IF6

2013-05-010

OAAI

HOSPITALIZATIONS AMONG BIPOLAR DISORDER PATIENTS BEFORE AND AFTER INITIATING LURASIDONE IN A COMMERCIALLY INSURED POPULATION

VALUE IN HEALTH

IF6

2013-05-010

OAAI

The relationship between use of antidepressants and resource utilization among patients with manic or mixed bipolar disorder episodes: Findings from a managed care setting

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2012-05-0113

PREAI

DEVELOPMENT AND CONTENT VALIDITY OF A PATIENT REPORTED OUTCOMES MEASURE TO ASSESS SYMPTOMS OF MAJOR DEPRESSIVE DISORDER (MDD)

VALUE IN HEALTH

IF6

2011-11-010

OAAI

ASSOCIATION OF ANTIDEPRESSANT THERAPY AND BIPOLAR DISORDER (BD)-RELATED RE-HOSPITALIZATIONS AMONG PATIENTS WITH MANIC OR MIXED BD EPISODES

VALUE IN HEALTH

IF6

2010-05-010

OAAI

Antidepressant Switching Among Adherent Patients Treated for Depression

PSYCHIATRIC SERVICES

IF3.2

2009-05-0123

PRE

Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2008-12-0158

PREAI